Innovation and Advanced Technology: We stand out for our ability to combine cannabinoids with other active ingredients, offering products that significantly improve the physical and mental well-being of our users. Supported by our own clinical studies that we conduct on the products.

Expert Team:

Alejandro Martí and Borja Vera, co-founders and co-CEOs, lead Votum World with a clear vision of growth and expansion, dedicating 100% of their resources and combining their experience in business management and team leadership.

Doctor Francisco Martínez, with over 25 years in sports surgery, strengthens clinical research and synergies in elite sports.

Doctor Sergio Navarro, with 20 years leading R&D in cosmetics, brings technological innovation.

Javier Abellán, with more than 10 years in market development, drives sales after working at prestigious consumer firms.

Rubén García, with 17 years in operational management, leads continuous improvement at Votum World.

Jorge Molina, a marketing and advertising specialist focused on increasing business sales through online channels, both on their own websites and on Amazon.

International Expansion: We are positioned to expand quickly and efficiently in the European market, taking advantage of the growing interest in CBD and its applications in health and cosmetics. The geographical expansion of Votum World products over the years (2026/2027 EU, LATAM) supports us:

• 2021: Murcia
• 2022: Murcia, nearby provinces.
• 2023: Spain, Italy (online).
• 2024: Spain, Mexico (branch), Italy, France, Portugal, Germany (online)

Differential Benefit: Our products offer superior benefits thanks to our clinical research and specialized formulations that differentiate us from our competitors, positioning us as leaders in a highly competitive sector.

In clinical studies conducted with Votum World products, we achieved a reduction in pain and inflammation by up to 59%, compared to 45% obtained with Ibuprofen. Therefore, Votum World presents a 14% improvement over ibuprofen.

This positions Votum World as a better clinical option for pain and inflammation treatment compared to NSAID options that harm the body.

Study results: https://journals.lww.com/ijds/fulltext/2024/16020/clinical_study_of_analgesic_and_anti_inflammatory.5.aspx 

Votum World's CBD cream significantly reduced masseter activity, pain intensity, and provided a greater analgesic effect compared to other products.

• The combination of CBD, Votum Cream, and physiotherapy achieved a 59% reduction.
• The combination of physiotherapy and 600 mg ibuprofen reduced pain by 45%.

Our ability to improve our differential benefit is ongoing. In 2024, we are conducting three new clinical studies with our own products.

• Muscle regeneration speed.
• Sleep behaviors and disorders.
• Inflammation and pain in pets (dogs).

Opportunity in a Growing Sector: With the increasing demand for effective natural health solutions, Votum World is strategically positioned to capture a significant share of this expanding market.

Revenue Data: The increase in sales is solid, demonstrating that the market is growing, and we are growing at a faster pace.

• 2021: €5.600
  
• 2022: €72.400
• 2023: €170.400
• 2024: €229.200

Votum World's compound annual growth rate: 158%

The CBD market has experienced a compound annual growth rate (CAGR) of over 20% in recent years, with an estimated total growth of 400% for the 2021-2028 period.

All this development has been carried out almost entirely with our own resources, countless hours of work, and a small capital contribution.

• 2021: 40.000 € (founders)
• 2022: 30.000 € (founders)
• 2023: 225.000 € (Pre-Seed)